Welcome to our dedicated page for Edesa Biotech news (Ticker: EDSA), a resource for investors and traders seeking the latest updates and insights on Edesa Biotech stock.
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of host-directed therapeutics for immuno-inflammatory diseases. Company announcements frequently highlight progress in its two main therapeutic areas, Medical Dermatology and Respiratory, giving investors and observers insight into the status of key clinical programs and funding arrangements.
On this page, readers can follow updates on Edesa’s dermatology pipeline, including news about EB06, an anti-CXCL10 monoclonal antibody candidate being developed as a therapy for vitiligo, and EB01 (1.0% daniluromer cream), a Phase 3-ready asset for moderate-to-severe chronic Allergic Contact Dermatitis. Disclosures often cover manufacturing milestones, regulatory interactions and plans for Phase 2 and Phase 3 clinical studies in these indications.
The news feed also captures developments in Edesa’s respiratory portfolio. This includes clinical data and regulatory context for paridiprubart (EB05), a monoclonal antibody being developed for Acute Respiratory Distress Syndrome (ARDS), as well as information on the U.S. government-funded “Just Breathe” platform study and Canadian government funding from the Strategic Innovation Fund. Announcements may detail Phase 3 study outcomes, safety findings, and the company’s exploration of additional uses for paridiprubart in chronic respiratory diseases and pulmonary fibrosis via EB07.
In addition to clinical and scientific news, Edesa’s releases include financial results, equity financings, at-the-market offering updates, and executive or board changes. Visitors can use this page to monitor how Edesa reports on its operating expenses, government contribution agreements, capital raises and conference participation. For those tracking EDSA, the news section provides a centralized view of the company’s disclosed milestones, strategic priorities and regulatory progress over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Edesa Biotech, a clinical-stage biopharmaceutical company (NASDAQ:EDSA), will participate in the Swiss Biotech Day on April 24-25, 2023, in Basel, Switzerland. This event will feature a delegation of Canadian officials and industry leaders. Interested parties can schedule meetings using the conference system or contact Edesa directly via email.
Edesa focuses on innovative treatments for inflammatory and immune-related diseases. Their leading candidate, EB05 (Paridiprubart), is in a Phase 3 study for Acute Respiratory Distress Syndrome (ARDS). Additionally, Edesa is developing an sPLA2 inhibitor, EB01, for chronic Allergic Contact Dermatitis and plans to conduct a Phase 2 trial of EB06 for vitiligo. The company emphasizes the importance of regulatory approvals and the inherent risks associated with clinical trials.
Edesa Biotech, Inc. (NASDAQ:EDSA) has announced that the World Health Organization (WHO) has adopted the international nonproprietary name "paridiprubart" for its monoclonal antibody candidate, EB05. This drug is currently in a Phase 3 study targeting hospitalized Covid-19 patients suffering from Acute Respiratory Distress Syndrome (ARDS). The drug exhibited an 84% reduction in mortality risk compared to a placebo during Phase 2 trials. The assignment of a generic name is seen as a vital step for Edesa's future marketing and regulatory filings, as paridiprubart is one of the first drugs to utilize WHO's new nomenclature system for monoclonal antibodies.
Edesa Biotech (NASDAQ:EDSA) announced participation in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 30, 2023. The event will feature a Fireside Chat with CEO Par Nijhawan, available to registered attendees at around 7:00 am ET. Edesa is a clinical-stage biopharmaceutical company focused on innovative treatments for inflammatory and immune-related diseases. Key developments include the Phase 3 study of monoclonal antibody EB05 for Acute Respiratory Distress Syndrome, and a Phase 2 trial for EB06 targeting vitiligo. For meeting arrangements, participants can contact their H.C. Wainwright representative or Edesa directly at investors@edesabiotech.com.
Edesa Biotech has been selected to present key clinical trial data for its EB01 drug candidate at the American Academy of Dermatology Association annual meeting from March 17-21, 2023. The presentation will occur on March 18, 2023, at 2:50 PM CT, showcasing significant results from a Phase 2B study involving 1.0% EB01 cream for treating moderate-to-severe chronic allergic contact dermatitis (ACD). The EB01 candidate, which targets sPLA2 pro-inflammatory enzymes, has previously shown efficacy in treating ACD. The meeting will also make presentation slides available shortly after the event.